NCT04253223View on ClinicalTrials.gov

A Study to Determine Safety and Efficacy of (REMD-477) in Controlling Hyperglycemia Due to Copanlisib

PHASE1TerminatedINTERVENTIONAL

Enrollment

1

Participants

Timeline

Start Date

April 7, 2020

Primary Completion Date

May 5, 2021

Study Completion Date

May 5, 2021

Conditions

Hyperglycemia Drug Induced

Interventions

BIOLOGICAL

REMD-477

REMD-477 will be administered as a subcutaneous injection for three weekly doses

Trial Locations (1)

27710

Duke University Medical Center, Durham

Sponsors

Lead Sponsor

Duke University

All Listed Sponsors

lead

Duke University

OTHER